Sunitinib and Reversible Posterior Leukoencephalopathy Syndrome: the usual suspect but not always the culprit. A case report.
Sunitinib is a vascular endothelium growth factor inhibitor. This agent may in some cases be associated with life-threatening complications. We report a case of a 64-year-old woman, with a topical recurrence of a papillary renal cell carcinoma (PRCC) who had been treated with sunitinib and presented...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2025-04-01
|
| Series: | Forum of Clinical Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/fco-2024-0002 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|